Table 1.
Patient baseline demographics.
| Characteristic | Total patients(n = 476) | Patients with prior NAT exposure(n = 132) | Patients without prior NAT exposure(n = 344) |
|---|---|---|---|
| Female, n (%) | 349 (73) | 92 (70) | 257 (75) |
| Age, mean (SD), years | 49 (11.0) | 50.2 (10.6) | 48.4 (11.4) |
| 18–29, n (%) | 17 (4) | 2 (2) | 15 (4) |
| 30–39, n (%) | 91 (19) | 23 (17) | 68 (20) |
| 40–49, n (%) | 135 (28) | 39 (30) | 96 (28) |
| 50–59, n (%) | 149 (31) | 42 (32) | 107 (31) |
| ≥60, n (%) | 84 (18) | 26 (20) | 58 (17) |
| Race, n (%) | |||
| White | 346 (73) | 104 (79) | 242 (70) |
| Black or African American | 35 (7) | 16 (12) | 19 (6) |
| Other | 21 (4) | 6 (5) | 15 (4) |
| Not reported owing to confidentiality | 74 (16) | 6 (5) | 68 (20) |
| Prior MS treatment, n (%) | 344 (72) | 132 (100) | 212 (62) |
| Prior MS treatment type, n (%) | |||
| NATa | 138 (29) | 132 (100) | 6 (2) |
| Glatiramer acetate | 66 (14) | 4 (3) | 62 (18) |
| Methylprednisolone | 60 (13) | 18 (14) | 42 (12) |
| Interferon | 83 (17) | 3 (2) | 80 (23) |
| Methylprednisolone sodium succinate | 27 (6) | 2 (2) | 25 (7) |
| Teriflunomide | 13 (3) | 1 (<1) | 12 (3) |
| Fingolimod | 13 (3) | 0 | 13 (4) |
| Other | 31 (7) | 3 (2) | 28 (8) |
MS: multiple sclerosis; NAT: natalizumab; SD: standard deviation.
aPrior MS treatment included at any treatment prior to initiating dimethyl fumarate; patients were categorized as “prior NAT” or “no prior NAT” based on NAT exposure within 6 months of initiating dimethyl fumarate.